<p>Dr. Kerry Reynolds is a physician at the Massachusetts General Hospital Cancer Center and Assistant Professor of Medicine at Harvard Medical School. She currently serves as the Director of the Severe Immunotherapy Complications Service, in addition to being the Clinical Director for the inpatient cancer services at Mass General Cancer Center.</p> <p>To learn more about the Severe Immunotherapy Complications Service and research program - click here - <a href="https://www.massgeneral.org/cancer-center/treatments-and-services/severe-immunotherapy-complications/">https://www.massgeneral.org/cancer-center/treatments-and-services/severe-immunotherapy-complications/</a>.</p> <p>Dr. Reynolds specializes in the care of hospitalized patients. Under her leadership, the Massachusetts General Cancer Center’s inpatient program evaluates and treats over 4,000 patients each year and serves as a core training experience for Harvard Medical School students, residents, and fellows each year.</p> <p>After completing her own residency, chief residency at Massachusetts General, and fellowship training in Oncology at Dana-Farber/Mass General Brigham Cancer Care, she joined the Harvard Medical School faculty in 2014, where she provides clinical care, supervises and educates trainees, participates in administrative affairs, and conducts research on severe toxicities associated with novel immunotherapy agents.</p> <p>Her short-term academic and primary research focus is to create a clinical database and tissue collection infrastructure to capture the full national history of immune related adverse events (irAEs), and uncover predictors that will identify patients at highest risk for adverse events associated with immunotherapy, or those destined to be refractory. The overall goal is to characterize these severe clinical presentations, understand the blueprint of cells/molecules driving these clinical presentations, and ultimately develop new therapeutics to improve the treatment of this unique patient population.</p> <p> </p>